Apolipoprotein A5 gene -1131T/C polymorphism is associated with the risk of metabolic syndrome in ethnic Chinese in Taiwan

Clinical Chemistry and Laboratory Medicine

Volumn 46, Issue 12, 2008, Pages 1714-1719

  Hsu, Lung An ^a   Ko, Yu Lin ^b   Chang, Chi Jen ^a   Teng, Ming Sheng ^b   Wu, Semon ^b   Hu, Chiao Feng ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

APOA5; High density lipoprotein cholesterol; Metabolic syndrome; Polymorphism; Triglycerides

Indexed keywords

APOLIPOPROTEIN A5; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALLELE; ARTICLE; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; ETHNICITY; FEMALE; GEL ELECTROPHORESIS; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION MAPPING; RISK FACTOR; TAIWAN;

ADULT; APOLIPOPROTEINS A; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POLYMORPHISM, GENETIC; QUESTIONNAIRES; TAIWAN;

EID: 57449089946     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2008.352     Document Type: Article

References (37)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
2. Bjorntorp P. Metabolic implications of body fat distribution. Diabetes Care 1991;14:1132-43.
3. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992;41:715-22.
4. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.
5. Bouchard C. Genetics and the metabolic syndrome. Int J Obes Relat Metab Disord 1995;19(Suppl 1):S52-9.
6. Heller DA, de Faire U, Pedersen NL, Dahlen G, McClearn GE. Genetic and environmental influences on serum lipid levels in twins. N Engl J Med 1993;328:1150-6.
7. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001;294:169-73.
8. van der Vliet HN, Sammels MG, Leegwater AC, Levels JH, Reitsma PH, Boers W, et al. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem 2001;276:44512-20.
9. van der Vliet HN, Schaap FG, Levels JH, Ottenhoff R, Looije N, Wesseling JG, et al. Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun 2002;295:1156-9.
10. Nabika T, Nasreen S, Kobayashi S, Masuda J. The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese. Atherosclerosis 2002;165:201-4.
11. Endo K, Yanagi H, Araki J, Hirano C, Yamakawa-Kobayashi K, Tomura S. Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren. Hum Genet 2002;111:570-2.
12. Baum L, Tomlinson B, Thomas GN. APOA5-1131T > C polymorphism is associated with triglyceride levels in Chinese men. Clin Genet 2003;63:377-9.
13. Lai CQ, Tai ES, Tan CE, Cutter J, Chew SK, Zhu YP, et al. The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore. J Lipid Res 2003;44:2365-73.
14. Aouizerat BE, Kulkarni M, Heilbron D, Drown D, Raskin S, Pullinger CR, et al. Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids. J Lipid Res 2003;44:1167-73.
15. Li GP, Wang JY, Yan SK, Chen BS, Xue H, Wu G. Genetic effect of two polymorphisms in the apolipoprotein A5 gene and apolipoprotein C3 gene on serum lipids and lipoproteins levels in a Chinese population. Clin Genet 2004;65:470-6.
16. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486-97.
17. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004;27:1182-6.
18. Hsu LA, Ko YL, Chang CJ, Hu CF, Wu S, Teng MS, et al. Genetic variations of apolipoprotein A5 gene is associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 2006;185:143-9.
19. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome warticle onlinex, 2005. Available at: http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf. Accessed May 10, 2008.
20. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation 2003;108:1546-51.
21. Havasi V, Szolnoki Z, Talián G, Bene J, Komlósi K, Maász A, et al. Apolipoprotein A5 gene promoter region T-1131C polymorphism associates with elevated circulating triglyceride levels and confers susceptibility for development of ischemic stroke. J Mol Neurosci 2006;29:177-83.
22. Maasz A, Kisfali P, Jaromi L, Horvatovich K, Szolnoki Z, Csongei V, et al. Apolipoprotein A5 gene IVS3 + G476A allelic variant confers susceptibility for development of ischemic stroke. Circ J 2008;72:1065-70.
23. Yamada Y, Kato K, Hibino T, Yokoi K, Matsuo H, Segawa T, et al. Prediction of genetic risk for metabolic syndrome. Atherosclerosis 2007;191:298-304.
24. Niculescu LS, Fruchart-Najib J, Fruchart JC, Sima A. Apolipoprotein A-V gene polymorphisms in subjects with metabolic syndrome. Clin Chem Lab Med 2007;45:1133-9.
25. Maász A, Kisfali P, Horvatovich K, Mohás M, Markó L, Csöngei V, et al. Apolipoprotein A5 T-1131C variant confers risk for metabolic syndrome. Pathol Oncol Res 2007;13:243-7.
26. Kao JT, Wen HC, Chien KL, Hsu HC, Lin SW. A novel genetic variant in the apolipoprotein A5 gene is associated with hypertriglyceridemia. Hum Mol Genet 2003;12:2533-9.
27. Matsunaga A, Arishima H, Niimura H, Zhang B, Uehara Y, Ohwaki K, et al. Strong linkage disequilibrium and association of -1131T > C and c.553G)T polymorphisms of the apolipoprotein A5 gene with hypertriglyceridemia in a Japanese population. Circ J 2007;715:746-52.
28. Kisfali P, Mohás M, Maasz A, Hadarits F, Markó L, Horvatovich K, et al. Apolipoprotein A5 IVS3 + 476A allelic variant associates with increased triglyceride levels and confers risk for development of metabolic syndrome in Hungarians. Circ J 2008;72:40-3.
29. Grallert H, Sedlmeier EM, Huth C, Kolz M, Heid IM, Meisinger C, et al. APOA5 variants and metabolic syndrome in Caucasians. J Lipid Res 2007;48:2614-21.
30. Weinberg RB, Cook VR, Beckstead JA, Martin DD, Gallagher JW, Shelness GS, et al. Structure and interfacial properties of human apolipoprotein A-V. J Biol Chem 2003;278:34438-44.
31. Schaap FG, Rensen PC, Voshol PJ, Vrins C, van der Vliet HN, Chamuleau RA, et al. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem 2004;279:27941-7.
32. Fruchart-Najib J, Bauge E, Niculescu LS, Pham T, Thomas B, Rommens C, et al. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun 2004;319:397-404.
33. Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 2000;7:325-31.
34. Goudriaan JR, Tacken PJ, Dahlmans VE, Gijbels MJ, van Dijk KW, Havekes LM, et al. Protection from obesity in mice lacking the VLDL receptor. Arterioscler Thromb Vasc Biol 2001;21:1488-93.
35. Szalai C, Keszei M, Duba J, Prohaszka Z, Kozma GT, Csaszar A, et al. Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease. Atherosclerosis 2004;173:109-14.
36. Waterworth DM, Ribalta J, Nicaud V, Dallongeville J, Humphries SE, Talmud P. ApoCIII gene variants modulate postprandial response to both glucose and fat tolerance tests. Circulation 1999;99:1872-7.
37. Ordovas JM, Schaefer EJ. Genetic determinants of plasma lipid response to dietary intervention: the role of the APOA1/C3/A4 gene cluster and the APOE gene. Br J Nutr 2000;83(Suppl 1):S127-36.